- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05703997
FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction (FASTIMMUNE)
FASTing-like Approach to Improve the Efficacy of Maintenance IMMunotherapy in Extensive-stage Small Cell Lung Cancer Patients Not Progressing on Chemoimmunotherapy Induction: the FASTIMMUNE Trial
Cyclic, 5-day calorie restriction is a safe metabolic intervention when combined with standard therapies in cancer patients, favorably reshaping peripheral blood and intratumor metabolism and immunity in a way that may improve the antitumor activity and efficacy of immunotherapy.
The goal of this clinical trial is to test if combining cyclic, 5-day calorie restriction with atezolizumab maintenance in patients with ES SCLC achieving at least stable disease after four cycles of induction atezolizumab plus carboplatin and etoposide chemoimmunotherapy may increase the efficacy of a standard first-line, chemo-immunotherapy approach in terms of patient PFS.
The main question it aims to answer is:
• does the combination of cyclic, 5-day calorie restriction with triweekly atezolizumab increase the 6 months PFS rate, as evaluated from maintenance treatment initiation, compared to historical results with standard atezolizumab maintenance monotherapy in patients with ES SCLC non-progressive after four cycles of first-line chemo-immunotherapy induction with atezolizumab plus carboplatin and etoposide?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Claudio Vernieri, MD, PhD
- Phone Number: (+39) 02 2390 3066
- Email: claudio.vernieri@istitutotumori.mi.it
Study Contact Backup
- Name: Giovanni Fucà, MD
- Phone Number: (+39) 02 2390 3066
- Email: giovanni.fuca@istitutotumori.mi.it
Study Locations
-
-
-
Milano, Italy, 20133
- Fondazione IRCCS Istituto Nazionale Tumori
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants who are able to comply with the requirements and restrictions listed in the Informed Consent Form and the study protocol (there is no separate Informed Consent Form for entering the maintenance phase)
- Signature of the informed consent form for those patients who have not previously participated to the induction phase of the study
- Age greater than or equal to 18 years and less than or equal to 75 years
- Willingness and ability to comply with the prescribed cyclic, 5-day calorie restriction regimen, the scheduled visits, treatment plans, laboratory tests and other procedures
- Histologically or cytologically confirmed diagnosis of small-cell lung cancer (SCLC).
- Radiological evidence of extensive-stage (ES) disease.
- Patient has available archival tumor tissue. Patients for whom only cytological material is available may be enrolled only if cytoincluded material is available.
- Patients must have received a first-line, chemoimmunotherapy induction with 4 triweekly cycles of atezolizumab plus carboplatin and etoposide, with the last cycle of induction chemoimmunotherapy administered not more than six weeks before the initiation of experimental maintenance treatment. Delays between cycles of chemoimmunotherapy due to the occurrence of AEs or other medical reasons are considered acceptable, provided that a total number of 4 cycles of chemoimmunotherapy with atezolizumab plus carboplatin and etoposide have been administered, and that there is no radiological evidence of disease progression.
- Radiological evidence of nonprogressive disease after chemoimmunotherapy induction with 4 triweekly cycles of atezolizumab plus carboplatin and etoposide.
- Patients with a history of treated CNS metastases are eligible, if there is no evidence of interim progression between the completion of CNS-directed therapy and the experimental maintenance treatment initiation, and if CNS metastases are asymptomatic.
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
- Presence of an adequate bone marrow and organ function
- Female patients of childbearing potential must agree to abstinence from heterosexual intercourse or to use two highly effective methods of contraception throughout the study and for at least six months after the end of the maintenance treatment.
Female patients are not of childbearing potential if they meet at least one of the following criteria:
- Have undergone a documented hysterectomy and/or bilateral oophorectomy
- Have medically confirmed ovarian failure
- Achieved post-menopausal status
- Male patients must agree to abstinence from heterosexual intercourse or to use two highly effective methods of contraception during sexual contact with a female with childbearing potential throughout the study and for at least six months after the end of the maintenance treatment.
Exclusion Criteria:
- Prior systemic treatment for ES SCLC, with the exception for first-line chemoimmunotherapy induction with 4 triweekly cycles of atezolizumab plus carboplatin and etoposide. Patients who received prior concurrent chemoradiotherapy for limited-stage (LS) disease may be enrolled if concurrent chemoradiotherapy was concluded at least three months before enrollment.
- Patient has not available archival tumor tissue or has only cytological material without cytoincluded material available.
- The patient has not recovered from immune-related AEs of grade 2 or higher from the induction phase with atezolizumab plus carboplatin and etoposide. Patients with adequately-treated, controlled, immune-related skin rash of grade 2 or adequately-treated, controlled, endocrinopathies of grade 2 on replacement therapy can be enrolled.
- Body mass index (BMI) < 19 kg/m2.
- Unintentional weight loss ≥ 5% in the previous 3 months, unless the patient has a BMI > 22 kg/m2 and weight loss has been lower than 10% at the time of enrollment in the study; or unintentional weight loss ≥ 10% in the previous 3 months, unless the patient has a BMI > 25 kg/m2 and weight loss has been lower than 15% at the time of the enrollment in the study. In all cases, weight must have been stable for at least one month before study enrollment.
- Baseline plasma glucose concentration ≤ 60 mg/dL (after at least 8 hours fasting)
- Diagnosis of any other malignancy within 2 years prior to enrollment, with the exception of adequately treated in-situ bladder cancer, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, ductal in-situ breast cancer, thyroid cancer or early-stage prostate cancer (all treatment of which should have been completed at least 6 months prior to enrollment)
- Asymptomatic and untreated, symptomatic or unstable CNS metastases as determined by CT-scan or MRI evaluation during screening and/or prior radiographic assessments.
- Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated but not clinically stable for ≥ 4 weeks prior to the experimental maintenance treatment initiation.
- Leptomeningeal disease.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).
- History of alcohol abuse.
- Active pregnancy or breastfeeding.
- Known active B or C hepatitis or human immunodeficiency virus (HIV) infection, or occasional finding of active hepatitis B/C infection during screening tests before experimental treatment initiation.
- Serious infections in the previous 4 weeks before the experimental maintenance treatment initiation.
- Active autoimmune diseases requiring systemic treatments (e.g., systemic steroids or immunosuppressants).
- Other medical conditions requiring active chronic therapy with systemic steroids at a dose ≥ 10 mg per day of prednisone or equivalent or other immunosuppressive medications within 14 days before the experimental maintenance treatment initiation.
- Adrenal replacement steroid doses ≥ 10 mg per day of prednisone or equivalent are permitted in the absence of active autoimmune disease
- Diagnosis of type 1 or 2 diabetes mellitus requiring pharmacologic therapy (including, but not limited to, insulin and secretagogues). A diagnosis of type 2 diabetes mellitus not requiring insulin and secretagogues on the judgment of a diabetologist and treated with metformin or alpha-glucosidase inhibitors (e.g., acarbose) is compatible with patient enrollment in the trial.
- Active gastric or intestinal ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small intestine resection.
Anamnesis of clinically significant heart disease including:
- angina pectoris, coronary bypass, symptomatic pericarditis, myocardial infarction in the previous 12 months from the beginning of experimental maintenance treatment.
- congestive heart failure NYHA class III-IV.
- cardiac arrhythmias, such as ventricular tachycardia, chronic atrial fibrillation, complete bundle branch block, high grade atrio-ventricular block like bi-fascicular block, type II Mobitz and third grade atrio-ventricular block, nodal arrhythmias, supra-ventricular arrhythmias.
- Previous episodes of symptomatic hypotension leading to loss of consciousness.
- Medical or psychiatric comorbidities rendering the patient not candidate to the clinical trial, according to the investigator's judgement.
- Other cardiac, liver, lung or renal comorbidities, not specified in the previous inclusion or exclusion criteria, but potentially exposing the patient to a high risk of lactic acidosis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Maintenance treatment with cyclic, 5-day calorie restriction plus atezolizumab
The experimental maintenance treatment will consist of:
The experimental maintenance treatment will be administered until the occurrence of unacceptable toxic effects, disease progression, consent withdrawal or patient death. Patients interrupting cyclic calorie restriction for any reason other than disease progression may continue the maintenance treatment with atezolizumab alone, if clinically indicated. |
Cyclic, 5-day, calorie-restricted (about 600 Kcal on day 1; about 300 Kcal on days 2 to 5), plant-based, low-protein, low-carbohydrate diet.
Atezolizumab 1200 mg administered intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS rate at 6 months
Time Frame: 6 months from experimental maintenance treatment initiation
|
The percentage of patients not experiencing disease progression or death from any cause after 6 months from experimental maintenance treatment initiation
|
6 months from experimental maintenance treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: Up to 75 months from experimental maintenance treatment initiation
|
The time between experimental maintenance treatment initiation and the date of disease progression or death from any cause
|
Up to 75 months from experimental maintenance treatment initiation
|
OS
Time Frame: Up to 75 months from experimental maintenance treatment initiation
|
The time between experimental maintenance treatment initiation and the date of patient death from any cause
|
Up to 75 months from experimental maintenance treatment initiation
|
Compliance
Time Frame: Up to 75 months from experimental maintenance treatment initiation
|
Percentage of patients undergoing minor and major deviations to the experimental dietary regimen; percentage of premature treatment withdrawals
|
Up to 75 months from experimental maintenance treatment initiation
|
Adverse events
Time Frame: Up to 75 months from experimental maintenance treatment initiation
|
Incidence, severity, seriousness and correlation to experimental dietary regimen/maintenance atezolizumab treatment of AEs, according of NCI-CTCAE, version 5.0; maximum toxicity grade experienced by each patient for each specific toxicity; percentage of patients experiencing grade 3-4 toxicity for each specific toxicity; patients with at least one SAE
|
Up to 75 months from experimental maintenance treatment initiation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma amino acids
Time Frame: At the beginning and at the end of the 5-day calorie restriction period of Cycle 1 and Cycle 2 and at the beginning of Cycle 5 and Cycle 8 of the experimental maintenance treatment (each experimental maintenance treatment cycle is 21 days)
|
Changes in the plasma concentration (as expressed in μM) of amino acids
|
At the beginning and at the end of the 5-day calorie restriction period of Cycle 1 and Cycle 2 and at the beginning of Cycle 5 and Cycle 8 of the experimental maintenance treatment (each experimental maintenance treatment cycle is 21 days)
|
Plasma fatty acids
Time Frame: At the beginning and at the end of the 5-day calorie restriction period of Cycle 1 and Cycle 2 and at the beginning of Cycle 5 and Cycle 8 of the experimental maintenance treatment (each experimental maintenance treatment cycle is 21 days)
|
Changes in the plasma concentration (as expressed in μg/ml) of fatty acids
|
At the beginning and at the end of the 5-day calorie restriction period of Cycle 1 and Cycle 2 and at the beginning of Cycle 5 and Cycle 8 of the experimental maintenance treatment (each experimental maintenance treatment cycle is 21 days)
|
Serum growth factors
Time Frame: At the beginning and at the end of the 5-day calorie restriction period of Cycle 1 and Cycle 2 and at the beginning of Cycle 5 and Cycle 8 of the experimental maintenance treatment (each experimental maintenance treatment cycle is 21 days)
|
Changes in the serum concentration of insulin (as expressed in μU/ml) and insulin-like growth factor 1 (as expressed in ng/ml)
|
At the beginning and at the end of the 5-day calorie restriction period of Cycle 1 and Cycle 2 and at the beginning of Cycle 5 and Cycle 8 of the experimental maintenance treatment (each experimental maintenance treatment cycle is 21 days)
|
Peripheral blood immune cell populations
Time Frame: At the beginning and at the end of the 5-day calorie restriction period of Cycle 1 and Cycle 2 and at the beginning of Cycle 5 and Cycle 8 of the experimental maintenance treatment (each experimental maintenance treatment cycle is 21 days)
|
Peripheral blood immune cell populations (as expressed as percentages relative to parental populations)
|
At the beginning and at the end of the 5-day calorie restriction period of Cycle 1 and Cycle 2 and at the beginning of Cycle 5 and Cycle 8 of the experimental maintenance treatment (each experimental maintenance treatment cycle is 21 days)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Filippo de Braud, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Publications and helpful links
General Publications
- Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
- Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021 Jan 14;7(1):3. doi: 10.1038/s41572-020-00235-0.
- Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, De Castro Carpeno J, Califano R, Nishio M, Orlandi F, Alatorre-Alexander J, Leal T, Cheng Y, Lee JS, Lam S, McCleland M, Deng Y, Phan S, Horn L. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021 Feb 20;39(6):619-630. doi: 10.1200/JCO.20.01055. Epub 2021 Jan 13.
- Ajona D, Ortiz-Espinosa S, Lozano T, Exposito F, Calvo A, Valencia K, Redrado M, Remirez A, Lecanda F, Alignani D, Lasarte JJ, Macaya I, Senent Y, Bertolo C, Sainz C, Gil-Bazo I, Eguren-Santamaria I, Lopez-Picazo JM, Gonzalez A, Perez-Gracia JL, de Andrea CE, Vicent S, Sanmamed MF, Montuenga LM, Pio R. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nat Cancer. 2020 Jan;1(1):75-85. doi: 10.1038/s43018-019-0007-9. Epub 2020 Jan 13.
- Vernieri C, Fuca G, Ligorio F, Huber V, Vingiani A, Iannelli F, Raimondi A, Rinchai D, Frige G, Belfiore A, Lalli L, Chiodoni C, Cancila V, Zanardi F, Ajazi A, Cortellino S, Vallacchi V, Squarcina P, Cova A, Pesce S, Frati P, Mall R, Corsetto PA, Rizzo AM, Ferraris C, Folli S, Garassino MC, Capri G, Bianchi G, Colombo MP, Minucci S, Foiani M, Longo VD, Apolone G, Torri V, Pruneri G, Bedognetti D, Rivoltini L, de Braud F. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discov. 2022 Jan;12(1):90-107. doi: 10.1158/2159-8290.CD-21-0030. Epub 2021 Nov 17.
- Ligorio F, Fuca G, Provenzano L, Lobefaro R, Zanenga L, Vingiani A, Belfiore A, Lorenzoni A, Alessi A, Pruneri G, de Braud F, Vernieri C. Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. Eur J Cancer. 2022 Sep;172:300-310. doi: 10.1016/j.ejca.2022.05.046. Epub 2022 Jul 8.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INT 207/22
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Carcinoma
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedCarcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell LungUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingPlatinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); Imago BioSciences, Inc., a subsidiary of Merck...SuspendedExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on Cyclic, 5-day calorie restriction
-
Universiti Sains MalaysiaCompletedNon-Alcoholic Fatty Liver Disease
-
University of Illinois at ChicagoNational Heart, Lung, and Blood Institute (NHLBI); Pennington Biomedical Research...CompletedObesity | Weight Loss | Coronary Heart DiseaseUnited States
-
Texas Tech UniversityCompleted
-
University of South CarolinaCompleted
-
St. Louis UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of CologneFresenius KabiCompletedAcute Renal FailureGermany
-
University of AarhusUniversity of Southern Denmark; University GhentRecruitingOverweight and ObesityDenmark
-
Washington University School of MedicineCompleted
-
University of California, San FranciscoNational Institutes of Health (NIH)CompletedModerately Overweight IndividualsUnited States